Loading...
XNASGRCL
Feb 21, Last price  
10.25USD
Name

Gracell Biotechnologies Inc

Chart & Performance

D1W1MN
XNAS:GRCL chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
-100.00%
000366,0000
Net income
-608m
L+30.40%
-60,793,000-132,176,000-197,161,000-465,880,000-607,509,000
CFO
-483m
L+58.48%
-61,856,000-135,393,000-198,149,000-304,550,000-482,648,000

Profile

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
IPO date
Jan 08, 2021
Employees
314
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
624,658
Unusual Expense (Income)
NOPBT
(624,658)
NOPBT Margin
Operating Taxes
22
Tax Rate
NOPAT
(624,680)
Net income
(607,509)
30.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
129,989
Long-term debt
77,020
Deferred revenue
Other long-term liabilities
6,879
Net debt
(1,251,195)
Cash flow
Cash from operating activities
(482,648)
CAPEX
(48,388)
Cash from investing activities
(48,332)
Cash from financing activities
33,324
FCF
(595,914)
Balance
Cash
1,458,204
Long term investments
Excess cash
1,458,204
Stockholders' equity
(1,551,530)
Invested Capital
3,117,153
ROIC
ROCE
EV
Common stock shares outstanding
107,486
Price
0.46
-61.92%
Market cap
49,444
-37.77%
EV
(1,201,751)
EBITDA
(547,150)
EV/EBITDA
2.20
Interest
6,737
Interest/NOPBT